Tempest Therapeutics, Inc. (TPST)

$1.54

-0.02 (-1.28%)
Rating:
Recommendation:
-
Symbol TPST
Price $1.54
Beta 0.000
Volume Avg. 0.01M
Market Cap 16.196M
Shares () -
52 Week Range 1.42-7.87
1y Target Est -
DCF Unlevered TPST DCF ->
DCF Levered TPST LDCF ->
ROE -98.60% Strong Sell
ROA -49.63% Strong Sell
Operating Margin -
Debt / Equity 135.95% Buy
P/E 0.18 Neutral
P/B 0.78 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest TPST news


Healthcare
Biotechnology
NASDAQ Capital Market

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.